<DOC>
	<DOCNO>NCT01282684</DOCNO>
	<brief_summary>The purpose study study safety tolerability single dose PLX5622 healthy , adult human volunteer . This first time PLX5622 take human .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics PLX5622 Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy adult male female subject , 1865 year age inclusive BMI 18 32 kg/m2 inclusive Female subject must surgically sterile postmenopausal past year negative urine pregnancy test . Male subject partner childbearing potential must willing use two method contraception , one must barrier method ( e.g . condom ) 90 day last study drug administration . Willing able remain clinical research unit require protocol Willing able provide write informed consent prior study related procedure comply study requirement History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease History presence disease , medical condition , surgery , may effect drug absorption , metabolism , distribution , excretion investigational product Laboratory test result ( include hepatic renal panel , complete blood count , chemistry panel , urinalysis ) investigator believe show clinically relevant significant abnormality normal reference range Any abnormality ECG ( include QTc â‰¥450 msec ) opinion investigator increase risk participate study History presence alcoholism drug abuse within year prior dose Tobacco use , either current within 3 month prior dose Use prescription medication herbal remedy within 14 day prior dose , use overthecounter medication vitamin within 7 day prior dose , unless approve Sponsor Donation whole blood within 56 day prior study Plasma donation within 7 day prior study Participation investigational device study receipt investigational drug within 4 week prior dose Positive urine test drug abuse Confirmed HIV , hepatitis B , hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>PLX5622</keyword>
</DOC>